Compare Cassava Sciences Inc (FLNA) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs IAC/Interactivecorp — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while IAC/Interactivecorp trades at $45.95 (market cap $3.41B). The key difference: IAC/Interactivecorp is far larger — about 64.2× Cassava Sciences Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | PPLI | |
|---|---|---|
Market Cap | $53.14M | $3.41B |
Sector | Health | Media |
52-Week High | $4.64 | $47.62 |
52-Week Low | $1.09 | $31.52 |
Enterprise Value | -$33.43M | $3.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
PPLI trades at $45.80, up 1.1% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative earnings in recent quarters, though 2026 projects a return to profitability. Analyst consensus is strongly bullish with a $55.40 price target, supported by potential acquisition interest from MGM Resorts. Cash flow volatility remains a concern with a significant net outflow of $820M in 2025.
The stock presents speculative upside based on acquisition potential and analyst optimism, but faces substantial execution risks amid declining revenue and negative earnings. Investors should weigh the strong institutional support against fundamental weaknesses and cash flow challenges when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
